4 6 6 4 3

论文已发表


注册即可获取德孚的最新动态



IF 收录期刊












更多详情 >>



停止接受任何荟萃分析文章 (Meta-analysis)

请注意:我们所有期刊已于 2019 年 4 月 1 日停止接受任何荟萃分析 (Meta-analysis)文章的提交。


会员计划

我们很高兴为机构提供一种切实的方法以支持开放获取并鼓励教师和研究人员通过开放获取模式尽可能广泛地传播他们的作品。

更多详情 >>

 

已发表论文

血清细胞骨架相关蛋白 4 作为诊断肝细胞癌的生物标志物

 

Authors Wang Y, Yu W, He M, Huang Y, Wang M, Zhu J

Received 1 October 2018

Accepted for publication 8 December 2018

Published 31 December 2018 Volume 2019:12 Pages 359—364

DOI https://doi.org/10.2147/OTT.S189425

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 2

Editor who approved publication: Dr Federico Perche

Background: Alpha-fetoprotein (AFP) is the most commonly applied biomarker for diagnosis of hepatocellular carcinoma (HCC), but the low sensitivity and specificity limit its clinical application. Cytoskeleton-associated protein 4 (CKAP4) is a novel oncogenic protein involved in the development and progression of HCC. This study aimed to evaluate whether measurement of circulating CKAP4 could improve diagnostic accuracy for HCC.
Methods: We analyzed data for patients with HCC, chronic hepatitis B infection, and cirrhosis and healthy controls (n=100 in each group), recruited from two centers between July 2013 and December 2015. Circulating levels of CKAP4 were measured with commercial enzyme-linked immunosorbent assay kits. Receiver operating characteristics were used to evaluate diagnostic accuracy.
Results: Serum concentrations of CKAP4 were significantly elevated in the HCC group, in comparison with the three control groups (all <0.001). The combined biomarker panel (AFP and CKAP4), created by binary logistic regression, presented better performance (area under the curve [AUC] 0.936, 95% CI [0.908–0.965], sensitivity 0.800, specificity 0.963) than AFP (AUC 0.875 [0.835–0.914], sensitivity 0.930, specificity 0.430, =0.001) or CKAP4 (AUC 0.821 [0.776–0.866], sensitivity 0.790, specificity 0.670, <0.001) alone to identify HCC, even though CKAP4 alone was not better than AFP (=0.093). Furthermore, the combined panel also presented a better performance even in identifying early HCC (AUC 0.922 [0.833–0.961]).
Conclusion: Serum CKAP4 is a novel biomarker for HCC, and it could complement AFP in improving diagnostic accuracy.
Keywords: alpha-fetoprotein, biomarker, cytoskeleton-associated protein 4, hepatocellular carcinoma




Figure 2 ROC curves for AFP, CKAP4, and the combination in the diagnosis of HCC and early-stage HCC.